Scarica l'app Stockscreener
38.10
1.68%
-0.65
Dopo l'orario di chiusura:
38.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$38.75
Aprire:
$38.18
Volume 24 ore:
1.08M
Relative Volume:
0.87
Capitalizzazione di mercato:
$7.87B
Reddito:
-
Utile/perdita netta:
$-505.61M
Rapporto P/E:
-13.76
EPS:
-2.7697
Flusso di cassa netto:
$-407.32M
1 W Prestazione:
-2.61%
1M Prestazione:
-4.49%
6M Prestazione:
+48.13%
1 anno Prestazione:
+135.19%
Intervallo 1D:
$37.52
$38.30
Intervallo di 1 settimana:
$37.52
$40.56
Portata 52W:
$14.58
$45.42
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
38.10 | 8.00B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Immunovant, Inc. (IMVT) Stock Analysis: Assessing the 21% Potential Upside with Strong Analyst Confidence - DirectorsTalk Interviews
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant (IMVT) Pulls Back 2.26% as Biotech Jitters Persist — $37.04 Support in FocusRating Change - Vinanet
Liquidity Mapping Around (IMVT) Price Events - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant Holds Near $40 as IMVT Consolidates Above Key SupportInverse ETF Flow - vinanet.vn
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Q1 2027 Earnings Call: Clinical Pipeline and Financial Outlook Take Center StageDividend Growth Analysis - vinanet.vn
Immunovant, Inc. Q1 2027 Earnings Call Summary - finance.yahoo.com
Immunovant Q1 Earnings Call Highlights - MarketBeat
Form 8K Immunovant Inc For: 6 August By Investing.com - Investing.com Nigeria
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingView
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - The Globe and Mail
Immunovant Fiscal Q1 Loss Widens - marketscreener.com
Immunovant, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss - marketscreener.com
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary - TradingView
Aug 06 (Reuters)Immunovant Q1 Operating Ex - Moomoo
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026 - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - manilatimes.net
Immunovant | 8-K: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - Moomoo
IMMUNOVANT Q1 NET INCOME USD -153.224 MILLION VS. IBES ESTIMATE USD -130.2 MILLION - Moomoo
Immunovant earnings up next as analysts eye pipeline pivot - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming DeadlineIMVT; HSACU; HSAC; and HSACW - TMX Newsfile
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00 - GuruFocus
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):